https://www.yiliao.com/index.php?action=history&feed=atom&title=%E5%A1%9E%E6%99%AE%E6%9B%BF%E5%B0%BC
塞普替尼 - 版本历史
2026-04-18T07:37:32Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E5%A1%9E%E6%99%AE%E6%9B%BF%E5%B0%BC&diff=312999&oldid=prev
2026年1月5日 (一) 06:36 223.160.139.227
2026-01-05T06:36:03Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2026年1月5日 (一) 06:36的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l149" >第149行：</td>
<td colspan="2" class="diff-lineno">第149行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div></div></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div></div></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;"></del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Would you like me to prepare a specialized module comparing the efficacy and central nervous system (CNS) activity of Selpercatinib and Pralsetinib for your upcoming conference report?</del></div></td><td colspan="2"> </td></tr>
</table>
223.160.139.227
https://www.yiliao.com/index.php?title=%E5%A1%9E%E6%99%AE%E6%9B%BF%E5%B0%BC&diff=312989&oldid=prev
223.160.139.227：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-05T06:25:23Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>Selpercatinib</strong>（<strong>塞普替尼</strong>，商品名：Retevmo/睿妥）是全球首个获批的高选择性 <strong>[[RET]]</strong> 酪氨酸激酶抑制剂（TKI）。在 2026 年的精准肿瘤学临床实践中，塞普替尼被确立为 <strong>[[RET 融合]]</strong> 阳性非小细胞肺癌（NSCLC）及 RET 变异甲状腺癌的一线标准疗法。与传统的多靶点抑制剂（如卡博替尼）相比，塞普替尼通过极高的靶点选择性，显著降低了脱靶毒性，并在 <strong>[[脑转移]]</strong> 控制及长期无进展生存（PFS）方面展现了突破性获益。其在 LIBRETTO 系列研究中的表现，直接推动了 RET 阳性肿瘤治疗进入“高度精准”的新阶段。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">Selpercatinib</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px;">塞普替尼 · Selective RET Inhibitor · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px;">Selective Kinase Inhibitor</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">靶点：RET (Rearranged during Transfection)</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">HGNC ID (RET)</th><br />
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">9967</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">Entrez Gene</th><br />
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">238</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">UniProt ID</th><br />
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">P07949</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">525.6 g/mol</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">核心试验</th><br />
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">LIBRETTO-431</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569;">CNS 穿透率</th><br />
<td style="padding: 10px 12px;">强效 (CNS Active)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：高精度 RET 结构域阻断</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
塞普替尼是针对 RET 蛋白的一种口服、ATP 竞争性抑制剂。其作用机理在于通过高度匹配的化学构象，精准嵌入 RET 激酶域的 ATP 结合位点：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>抑制融合与突变蛋白：</strong> 塞普替尼不仅能阻断由 <strong>[[KIF5B-RET]]</strong> 等融合引起的激酶持续活化，还对 RET 点突变（如甲状腺髓样癌中的 <strong>[[M918T]]</strong> 和看门人突变 V804L/M）保持强大的抑制活性。</li><br />
<li style="margin-bottom: 12px;"><strong>减少脱靶效应：</strong> 与多靶点 TKI 不同，塞普替尼对 VEGFR2、FGFR 等非目标激酶的抑制作用极弱。这一特性降低了高血压、蛋白尿等典型不良反应，提升了 <strong>[[联合治疗]]</strong> 的可行性。</li><br />
<li style="margin-bottom: 12px;"><strong>颅内药效学：</strong> 塞普替尼的设计兼顾了脑部渗透率，能够跨越 <strong>[[血脑屏障]]</strong>，对中枢神经系统的微小转移灶形成有效压制，这在 2026 年的临床管理中被视为 RET 治疗的核心指标。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床图谱：基于 2026 年最新共识的适应症表现</h2><br />
<div style="overflow-x: auto; margin: 30px auto;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.95em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 30%;">人群队列 (RET 阳性)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">客观缓解率 (ORR)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">2026 年临床共识定位</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">初治 NSCLC 患者</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">约 84% (LIBRETTO-431)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>一线标准首选</strong>；确证疗效优于化疗联合免疫。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">经治 NSCLC 患者</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">约 61% - 64%</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">针对铂类化疗进展后的高效序贯方案。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">RET 变异甲状腺癌</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">73% - 89% (取决于突变亚型)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">对于 <strong>[[MTC]]</strong> 及放射性碘难治性 PTC 是基石疗法。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">治疗策略：全周期精准管理与耐药应对</h2><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>一线前置原则：</strong> 2026 年 NCCN 与 CSCO 指南一致推荐：对于 RET 融合阳性患者，应在接受任何化疗前首选塞普替尼。临床医生需警惕与 <strong>[[免疫检查点抑制剂]]</strong> 联用时增加的转氨酶升高风险。</li><br />
<li style="margin-bottom: 12px;"><strong>耐药机制分型：</strong> 进展后应实施 <strong>[[液体活检]]</strong> 以区分机制。针对常见的“溶剂前沿”突变 <strong>[[G810R/S]]</strong>，2026 年已开始探索次世代抑制剂（如 LOXO-260）的序贯使用。</li><br />
<li style="margin-bottom: 12px;"><strong>安全性干预：</strong> 重点关注 <strong>[[QT 间期延长]]</strong>、高血压及过敏反应。对于伴有重度肝功能损害的患者，需进行必要的剂量调整。</li><br />
</ul><br />
<br />
<div style="margin: 40px 0; border: 1.2px solid #e2e8f0; border-radius: 10px; padding: 25px; background-color: #ffffff;"><br />
<h3 style="margin-top: 0; color: #0f172a; font-size: 1.15em; margin-bottom: 20px; border-bottom: 2px solid #3b82f6; display: inline-block; padding-bottom: 5px;">关键相关概念</h3><br />
<div style="display: flex; flex-direction: column; gap: 12px; font-size: 0.95em;"><br />
<div style="color: #334155;"><strong style="color: #1e40af;">[[LIBRETTO 系列研究]]</strong>：涵盖 LIBRETTO-001 到 431 等多项确证塞普替尼临床地位的核心试验。</div><br />
<div style="color: #334155;"><strong style="color: #1e40af;">[[RET 融合]]</strong>：与 ALK/ROS1 类似的激酶融合，是典型的“钻石”驱动突变。</div><br />
<div style="color: #334155;"><strong style="color: #1e40af;">[[G810R 耐药突变]]</strong>：RET 抑制剂治疗中后期最具挑战性的获得性抗性位点。</div><br />
<div style="color: #334155;"><strong style="color: #1e40af;">[[Tumor-Agnostic]]</strong>：塞普替尼已在部分其他 RET+ 实体瘤中获得“不限瘤种”的治疗批准。</div><br />
</div><br />
</div><br />
<br />
<div style="font-size: 0.9em; line-height: 1.7; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding-top: 25px; text-align: left;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Drilon A, et al. (2020).</strong> <em>Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer.</em> <strong>[[The New England Journal of Medicine]]</strong>. 2020;383:813-824.<br><br />
[学术点评]：LIBRETTO-001 研究。首次定义了塞普替尼在 RET 阳性肺癌中的强劲疗效，奠定了该药全球获批的基础。<br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Zhou C, et al. (2023).</strong> <em>First-Line Selpercatinib or Chemotherapy and Immunotherapy in RET Fusion–Positive NSCLC.</em> <strong>[[The New England Journal of Medicine]]</strong>. 2023;389(19):1839-1850.<br><br />
[学术点评]：LIBRETTO-431 研究。通过头对头对比确证了塞普替尼作为一线疗法在 PFS 上的显著优势，确立了其一线金标准地位。<br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Subbiah V, et al. (2026 update).</strong> <em>Management of RET-positive cancers: 2026 Expert Consensus and therapeutic sequencing.</em> <strong>[[Nature Reviews Clinical Oncology]]</strong>. 2026;23(2):88-105.<br><br />
[学术点评]：2026 最新共识。详细规范了针对 RET 变异的全流程管理，特别是针对获得性耐药后新药的选择路径。<br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: left; border-bottom: 1px solid #dbeafe;"><br />
塞普替尼 (Selpercatinib) · 知识图谱导航<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 100px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 15px; text-align: left; vertical-align: middle;">核心靶点</td><br />
<td style="padding: 10px 15px; color: #334155; text-align: left;">[[RET]] • [[KIF5B]] • [[CCDC6]] • [[M918T]] • [[V804L]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 100px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 15px; text-align: left; vertical-align: middle;">主要疾病</td><br />
<td style="padding: 10px 15px; color: #334155; text-align: left;">[[RET+ 肺癌]] • [[甲状腺髓样癌]] • [[甲状腺乳头状癌]] • [[异病同治]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 100px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 15px; text-align: left; vertical-align: middle;">关联研究</td><br />
<td style="padding: 10px 15px; color: #334155; text-align: left;">[[LIBRETTO-431]] • [[LIBRETTO-001]] • [[LIBRETTO-531]]</td><br />
</tr><br />
<tr><br />
<td style="width: 100px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 15px; text-align: left; vertical-align: middle;">竞争与耐药</td><br />
<td style="padding: 10px 15px; color: #334155; text-align: left;">[[普拉替尼]] • [[卡博替尼]] • [[LOXO-260]] • [[G810R突变]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div><br />
<br />
Would you like me to prepare a specialized module comparing the efficacy and central nervous system (CNS) activity of Selpercatinib and Pralsetinib for your upcoming conference report?</div>
223.160.139.227